Navigation Links
Anthony S. Fauci awarded Lasker Award for Public Service
Date:9/18/2007

Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), has been awarded the 2007 Mary Woodard Lasker Award for Public Service for his role in developing two major U.S. public health programs, in AIDS and biodefense. The award will be presented on Friday, September 28th during a luncheon ceremony in New York City.

Dr. Fauci is honored for his role in helping develop the Presidents Emergency Plan for AIDS Relief (PEPFAR), the largest public health program in history devoted to a single disease, as well as Project Bioshield, designed to accelerate the research, development, purchase and availability of medical countermeasures against the effects of biological, chemical, radiological and nuclear agents.

In nearly four decades of service to NIH, Tony Fauci has made innumerable scientific contributions that have improved the health of millions of people in this country and abroad, says NIH Director Elias A. Zerhouni, M.D. As a clinician, researcher, and scientific leader, Dr. Fauci has channeled his intellect, compassion, and vision into discoveries and research programs that have transformed medicine and public health.

Earlier this year, Dr. Fauci received two other major honors: the George M. Kober Medal of the Association of American Physicians for his work in clinical medicine, and the National Medal of Science, for his research into the pathogenesis of human immunodeficiency virus (HIV) disease.

Dr. Zerhouni adds, It is fitting to have Tony recognized with a trifecta of awards related to the three fundamental NIH missions: basic research, clinical research, and public service. It is hard to think of anyone more deserving of this award.

Dr. Faucis tenure as NIAID director began in 1984. For nearly 23 years, he has overseen the extensive NIAID research portfolio of basic and applied research to prevent, diagnose and treat infectious and immunologic dise
'/>"/>

Contact: Patricia Conrad
conradpa@niaid.nih.gov
202-906-0995
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. TGen awarded $7.1 million to accelerate brain disease research
2. NJIT Presidential Award winner takes stem cell research another step
3. Virtual microscopy project wins educational technology award
4. New push for public health, AIDS spending at African Union summit
5. Wiley announces publication of Databasing the Brain
6. BioMed Central welcomes the new National Institutes of Health public access policy
7. Not-for-profit publishers call NIH public access rule a missed opportunity
8. NIH Calls on Scientists to Speed Public Release of Research Publications
9. CoPub Mapper: mining MEDLINE based on search term co-publication
10. AIDS Public Awareness Campaign Expands Following Report Of Rapidly Progressive HIV
11. DOE JGI launches IMG public online microbial genome data clearinghouse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
(Date:7/11/2014)... marginal division of the striatum is also involved ... degree of substance P in the striatal marginal ... and his team, College of Biophotonics, South China ... substance P receptor, neurokinin 1 was highly expressed ... normal rats. Unilateral or bilateral injection of an ...
(Date:7/11/2014)... Using spider toxins to study the proteins that let ... say they have stumbled upon a biological tactic that ... insect plagues in a safe and environmentally responsible way. ... be lethal for one species and harmless for a ... target specific pests without harming beneficial species like bees. ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... understanding of the process cells use to ensure that ... of each chromosome ?a process that must be exquisitely ... retardation. The new work reveals how gluelike protein complexes ... meiosis ?the specialized cell division process that produces sperm ...
... first birthday, according to new infant mortality statistics for ... (NCHS). , The infant mortality rates showed no significant ... first time since 1958. , In 2003, the ... live births, which was statistically unchanged from the 2002 ...
... Nerve signals relayed directly to the pancreas after eating ... sugar control, according to a report in the June ... sensitivity to such signals might offer a new approach ... which the pancreas cells that produce insulin, or beta ...
Cached Biology News:What controls stickiness of 'smart' chromosomal glue 2What controls stickiness of 'smart' chromosomal glue 3What controls stickiness of 'smart' chromosomal glue 4US infant mortality rate fails to improve 2Increased sensitivity to nerve signals keeps diabetes at bay 2
(Date:7/12/2014)... (PRWEB) July 12, 2014 ... various reagents used in the life science ... the life science reagents market towards remarkable ... manufacturers and providers of life science reagents. ... Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global ...
(Date:7/11/2014)... 11, 2014 , Not for release, ... or from any jurisdiction where to do so would constitute ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ...  Shire confirms it has held a meeting with representatives of ... without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 BCC Research ... DIGITAL POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS ... (PCR) technology reached nearly $140 billion in 2013. This ... registering a five-year compound annual growth rate (CAGR) of ... number of interesting and exciting possibilities within the broader ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... World-class investigators affiliated with US Oncology Research ... and displayed Dec. 6-10 at the Henry B. Gonzales ... Cancer Symposium ( SABCS ), an international scientific symposium ... in breast cancer. (Logo: http://photos.prnewswire.com/prnh/20110912/DA65711LOGO ) ...
... Calif., Dec. 1, 2011  AtheroNova Inc. (OTCBB: AHRO) ... and development of compounds to regress atherosclerotic plaque, ... ("CardioNova"), a Russian subsidiary of Maxwell Biotech Group ... for AtheroNova,s AHRO-001 lead compound has been ratified ...
... 2011 The collaboration of two leading cell image ... facility for archiving, sharing, and analyzing microscope images in ... and the National Center for Microscopy and Imaging Research ... have joined forces to provide a unified interface. This ...
Cached Biology Technology:US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium 2US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium 3US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium 4AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug 2AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug 3Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public 2Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public 3
... calibration, and validation (MCV) plate ... plate used for hands-free startup, ... using the Bio-Plex suspension array ... for use with Bio-Plex Manager ...
... first biological reagent that eliminates ... not just by inhibiting growth. ... agent that can be used ... The cytotoxicity of Mynox is ...
A component of the Acridinium protein labeling kit....
... NHS ester can be used ... acids. The covalently bound acridinium ... in the presence of hydrogen ... can be used as a ...
Biology Products: